1 recruiting, 1 withdrawn. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
Follow Phase I: new trials by email Literature Review of Phase I trials Research Report on Phase I
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation Psilocybin (Usona Institute), Inactive Placebo (Usona Institute) - Phase I | Phase 1 | Recruiting | Brown University | 24 | 2026-11-01 | 2026-10-08 |
| A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia Fludarabine, Cytarabine, G-CSF - Phase I, FLAG Chemotherapy | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2026-04-27 | 2026-05-07 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Cytarabine (1) · Granulocyte Colony-Stimulating Factor (1) · Lisaftoclax (1) · Psilocybin (1) · fludarabine (1) · pelcitoclax (1)
Brown University (1) · M.D. Anderson Cancer Center (1)
United States (1)